BLADE-PCI: Novel Drug Therapy Fails to Outperform Placebo in Reducing Neointimal Hyperplasia in Diabetes Patients Undergoing PCI
Novel therapy using liposomal alendronate failed to meet its primary endpoint of decreasing neointimal hyperplasia (NIH) and did not improve clinical outcomes in diabetes patients undergoing percutaneous coronary intervention (PCI), according to results presented Sunday at Transcatheter Cardiovascular Therapeutics 2019 in San Francisco.